Lymphoid neoplasms are one of the most common malignancies worldwide (
1). Gastrointestinal (GI) tract is the most common site for extranodal lymphoma with a rate between 4% and 20% of all NHL cases (
2-
6). Primary GI lymphoma is rare and accounts for 1% to 4% of all GI malignancies (
1-
3) especially in elderly male subjects (
7). The distribution and the prognosis in various regions are different, and better prognosis is expected in Europe and the United States due to earlier diagnosis and better treatment (
1) that is not feasible in Asian and developing countries. In the GI part, stomach is the most commonly involved site and thereafter the ileocecal, small intestine, pharynx, colon, and occasionally the esophagus are affected (
3-
5). Diagnosis should be made according to the Dawson’s criteria that include (1) absence of peripheral lymphadenopathy at the time of presentation; (2) lack of enlarged mediastinal lymph nodes; (3) normal total and differential white blood cell count; (4) predominance of bowel lesion at the time of laparotomy with only lymph nodes obviously affected in the immediate vicinity; and (5) no lymphomatous involvement of liver and spleen (
4,
5,
7). The stomach is the main GI location in 55% to 75% of GI lymphoma cases (
5). Also, lymphoma is responsible for 1% to 7% of all gastric malignancies (
3). It is generally DLBCL or MALT lymphoma (MALToma) (
1,
8-
10). In 15% to 35% of patients with GI lymphoma, the small intestine or ileocecal region are primary sites (
3). Lymphoma is responsible for 25% of small intestinal neoplasms and the ileum is more affected in comparison with the duodenum. Colon is the principal involved location in 3% to 20% of GI lymphoma especially in the cecum and rectum and also sometimes the lymphoma is multifocal (
3). Lymphoma in the esophagus is rare (
3). The majority of the cases are seen in elderly and middle-aged subjects with a female predominance and primary pancreatic lymphoma (PPL) is rare and responsible for only less than 0.7% of NHL cases (
3)).